New shades of capitalism are emerging in China's tuckered out stock market as companies, at Beijing's behest, buy back their shares and pay record dividends to investors lying in wait for a so-far evasive rebound.

After China's DeepSeek prompts AI rethink, Nvidia stock slides. Follow along for live updates on stocks and other markets, including the Dow Jones Industrial Average, S&P 500 and Nasdaq Composite.

Currency traders looking for their next big idea could do worse than talk to Wong, who runs a news stand in Hong Kong’s Central District.

Japan's Nikkei 225 futures pointed to a stronger open for the market. The futures contract in Chicago is currently at 40,260 and its counterpart in Osaka last traded at 40,480 compared to the index's previous close of 39,931.98.

The historic legislation for Basic Law Article 23, aimed at safeguarding national security and ensuring Hong Kong's stability and development, has topped a list of the ten most significant policies by the Hong Kong Special Administrative Region (HKSAR) government in 2024.

US President Donald Trump had threatened 60% tariffs on Chinese goods on his campaign trail.

The Company makes available through the Investor Relations section of its internet website at http://ir.yumchina.com its filings with the HKEX as soon as reasonably practicable after electronically filing such materials with the HKEX. These filings may also be obtained by visiting the HKEX's website at http://www.hkex.com.hk.

The Chinese government is trying to encourage people to spend more by ensuring that share prices will rise, ordering pensions and mutual funds to invest more in domestic stocks to help jolt its languid markets out of the doldrums.

Restructuring terms allow the Chinese developer to effectively cut its annual borrowing costs to 4.12 per cent from 9.6 per cent.

Investors dumped technology stocks in premarket trading Monday, sending U.S. indexes sharply lower after Chinese artificial intelligence startup DeepSeek demonstrated a chatbot that it says rivals the top versions from OpenAI and Google for a fraction of the cost.

Chinese biotech Ascentage Pharma has taken the first US biotech initial public offering (IPO) of 2025 over the finish line, raising $126 million for its pipeline of small-molecule cancer drugs.